NO20075463L - Tetrahydrotiopyranopyrazolcannabinoidmodulatorer kryssreferanse til beslektede soknader - Google Patents

Tetrahydrotiopyranopyrazolcannabinoidmodulatorer kryssreferanse til beslektede soknader

Info

Publication number
NO20075463L
NO20075463L NO20075463A NO20075463A NO20075463L NO 20075463 L NO20075463 L NO 20075463L NO 20075463 A NO20075463 A NO 20075463A NO 20075463 A NO20075463 A NO 20075463A NO 20075463 L NO20075463 L NO 20075463L
Authority
NO
Norway
Prior art keywords
tetrahydrotiopyranopyrazole
modulators cross
cannabinoid modulators
related societies
societies
Prior art date
Application number
NO20075463A
Other languages
English (en)
Norwegian (no)
Inventor
Fina Liotta
Michael P Wachter
Mingde Xia
Huajun Lu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20075463L publication Critical patent/NO20075463L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20075463A 2005-03-31 2007-10-29 Tetrahydrotiopyranopyrazolcannabinoidmodulatorer kryssreferanse til beslektede soknader NO20075463L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66689805P 2005-03-31 2005-03-31
PCT/US2006/009424 WO2006107561A1 (fr) 2005-03-31 2006-03-16 Modulateurs cannabinoides a base de tetrahydrothiopyrano pyrazole

Publications (1)

Publication Number Publication Date
NO20075463L true NO20075463L (no) 2007-12-21

Family

ID=36587178

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075463A NO20075463L (no) 2005-03-31 2007-10-29 Tetrahydrotiopyranopyrazolcannabinoidmodulatorer kryssreferanse til beslektede soknader

Country Status (18)

Country Link
US (2) US20060223798A1 (fr)
EP (1) EP1863479B1 (fr)
JP (1) JP5127697B2 (fr)
KR (1) KR20080004559A (fr)
CN (1) CN101189007A (fr)
AT (1) ATE416768T1 (fr)
AU (1) AU2006232945B2 (fr)
BR (1) BRPI0609790A2 (fr)
CA (1) CA2603104A1 (fr)
CO (1) CO6321135A2 (fr)
CR (1) CR9479A (fr)
DE (1) DE602006004197D1 (fr)
EA (1) EA200702130A1 (fr)
IL (1) IL186430A0 (fr)
MX (1) MX2007012233A (fr)
NO (1) NO20075463L (fr)
WO (1) WO2006107561A1 (fr)
ZA (1) ZA200709342B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863903B (zh) * 2010-06-08 2014-03-12 沈阳药科大学 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2003035005A2 (fr) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
KR20080004559A (ko) 2008-01-09
CA2603104A1 (fr) 2006-10-12
EP1863479A1 (fr) 2007-12-12
US20080085899A1 (en) 2008-04-10
AU2006232945B2 (en) 2012-02-23
BRPI0609790A2 (pt) 2010-04-27
DE602006004197D1 (de) 2009-01-22
MX2007012233A (es) 2008-03-18
CR9479A (es) 2008-09-09
EA200702130A1 (ru) 2008-04-28
ZA200709342B (en) 2009-09-30
IL186430A0 (en) 2008-01-20
AU2006232945A1 (en) 2006-10-12
JP2008535829A (ja) 2008-09-04
EP1863479B1 (fr) 2008-12-10
CO6321135A2 (es) 2011-09-20
JP5127697B2 (ja) 2013-01-23
US20060223798A1 (en) 2006-10-05
US7524964B2 (en) 2009-04-28
CN101189007A (zh) 2008-05-28
ATE416768T1 (de) 2008-12-15
WO2006107561A1 (fr) 2006-10-12

Similar Documents

Publication Publication Date Title
NO20064810L (no) Tetrahydro-indazolcannabinoid-modulatorer
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
TW200610528A (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
NO20070910L (no) Pyrrolderivater som farmasoytiske middel
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
NO20081810L (no) Modulatorer av metabolisme og behandling av lidelser relatert dertil
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
NO20082505L (no) Substtuert 5-heteroaryl-1-fenyl-pyrazol-cannabinoid-modulatorer
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
ATE458480T1 (de) Hexahydro-cyclooctyl-pyrazol-cannabinoid- modulatoren
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
WO2006020680A3 (fr) Composes heterocycliques comme agents pharmaceutiques
WO2010021717A3 (fr) Inhibiteurs de la protéase du vhc
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
DE502006001195D1 (de) Transdermales therapeutisches system zur verabreichung von analgetika
WO2009023653A3 (fr) Modulateurs de cannabinoïdes de type 5-vinylphényle-1-phényle-pyrazole substitués
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
NO20092134L (no) Kombinasjonsprodukt for bruk i behandling av inflammatoriske lidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application